Company intelligence / Profile preview

Excellen Medical Technology

Ownership: Private
Development stage: Commercial

Overview

Excellen Medical developed the first approved blood methylation diagnostic kit for early lung cancer screening in China. The test uses 5ml peripheral blood to detect ctDNA with high sensitivity and specificity. It has received NMPA Class III medical device registration certification and CE marking, with clinical sensitivity of 86.83%, specificity of 95.59%, and total coincidence rate of 92.33%[8].

Therapeutic areas: Oncology
Modalities: Diagnostic kit
Industry: Molecular Diagnostics

Partnerships

Extensive collaborations with top research institutions and hospitals domestically and internationally[8]

Beyond the preview

Go deeper on Excellen Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excellen Medical Technology.

Explore the full profile